Recruiting
PHASE2
INTERVENTIONAL
NCT06994338
Tirzepatide for Alcohol Use Disorder
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Tirzepatide injections (2.5mg, 5.0mg)
Name:
Placebo injections
Type:
DRUG
Description:
Placebo injections
Primary Outcomes
Measure:
Number of heavy drinking days
TimeFrame:
Last 4 weeks of treatment (Weeks 5-8)
Description:
Number of heavy drinking days (NHDD) during the last four weeks of treatment (treatment Weeks 5-8), as measured by the Timeline Followback interview. NHDD is defined as the total number of days on which participants consumed 5 or more drinks (for men) or 4 or more drinks (for women). The analysis of NHDD will control for baseline NHDD (defined as NHDD in the four weeks preceding treatment).
Trial Information
NCT ID
NCT06994338
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
University of Southern California
Last Updated
December 15, 2025